Technology Video Quick Links XT-8   Warfarin   Cystic Fibrosis

2009 AACC Poster Development and evaluation of an eSENSOR® genotyping test with an extended warfarin sensitivity and resistance panel: addition of the CYP450 4F2 rs2108622 (V433M) and CYP2C9 *5 markers. 2009 AACC Poster Development and evaluation of an eSENSOR® genotyping test for cystic fibrosis on the XT-8 instrument. IVD Technology: This article discusses a new eSensor system that consists of the eSensor XT-8 instrument and micro­fluidic cartridges. The discovery of a new genetic marker for warfarin dosage has just been described in the peer-reviewed journal, Blood Online.

News Events 28 May 2010 Update re Scheme of Arrangement 27 May 2010 Update re: Scheme timetable 27 May 2010 Update re Scheme of Arrangement 26 May 2010 Update re. Scheme of Arrangement 26 May 2010 Update re. Scheme of Arrangement 17 May 2010 Update regarding Scheme timetable, listing of GenMark on NASDAQ and GenMark Fundraising 28 April 2010 Scheme of Arrangement update: results of Osmetech Shareholder Meetings 26 April 2010 Osmetech plc Receives 510(k) Clearance for the eSensor® Thrombophilia Risk Test 20 April 2010 Adjournment of Osmetech Shareholder Meetings 19 April 2010 Proposed adjournment of Osmetech Shareholder Meetings 1 April 2010 Director exercise of options and Total Voting Rights 31 March 2010 Posting of scheme document 19 March 2010 Proposed change of Group structure, listing and fundraising on the NASDAQ Global Market and cancellation of AIM trading facility 19 March 2010 Osmetech plc preliminary results for the 12 months ended 31 December 2009 15 February 2010 Total Voting Rights and Share Capital 20 January 2010 Disclosure of Significant Shareholdings 30 December 2009 Disclosure of Significant Shareholdings 24 December 2009 Disclosure of Significant Shareholdings 24 December 2009 Grant of Warrants and Share Options to Directors 24 December 2009 Director/PDMR Shareholding 21 December 2009 Result of GM 9 December 2009 Osmetech Names John Bellano Sr. Vice President Commercial Operations 1 December 2009 Proposed Placing of 479,800,841 New Ordinary Shares 24 November 2009 Change in Details of a Director 8 October 2009 Grant of Warrants and Share Options to Directors 24 September 2009 Osmetech and Fisher Agree to Terminate US Distribution Agreement 24 September 2009 Disclosure of Significant Shareholdings 17 September 2009 Interim results for the 6 months ended 30 June 2009 7 September 2009 Disclosure of Significant Shareholdings 1 September 2009 Board Changes 25 August 2009 Osmetech a Finalist for 2009 ABBY Award 17 August 2009 Disclosure of Significant Shareholdings 30 July 2009 Osmetech’s eSensor XT-8 System wins ‘R&D 100 Award’ 20 July 2009 Disclosure of Significant Shareholdings 17 July 2009 Board Change 14 July 2009 Disclosure of Significant Shareholdings 9 July 2009 FDA clears Osmetech’s Cystic Fibrosis Genotyping Test 1 July 2009 Disclosure of Significant Shareholdings 1 July 2009 Christopher Gleeson Appointed Chairman 25 June 2009 £5.5m placing of new ordinary shares 8 June 2009 Osmetech’s exclusive Warfarin CYP4F2 biomarker included in leading warfarindosing.org algorithm 26 May 2009 Disclosure of Significant Shareholdings 22 May 2009 Disclosure of Significant Shareholdings 18 May 2009 Disclosure of Significant Shareholdings 14 May 2009 Osmetech’s eSensor XT-8 platform wins Medical Design Excellence Award 12 May 2009 Osmetech chosen as principal supplier for a major clinical trial 11 May 2009 Osmetech submits swine flu test to the FDA 5 May 2009 Results of AGM 1 April 2009 Osmetech and Fisher HealthCare sign U.S. distribution agreement 1 April 2009 Osmetech plc preliminary results for the 12 months ended 31 December 2008 23 January 2009 Disclosure of Significant Shareholdings 8 January 2009 Disclosure of Significant Shareholdings 6 January 2009 Extended warfarin sensitivity test submitted for FDA approval 5 January 2009 Disclosure of Significant Shareholdings 31 December 2008 Changes in Board 22 December 2008 Result of EGM 17 December 2008 Disclosure of Significant Shareholdings 15 December 2008 Disclosure of Significant Shareholdings 10 December 2008 Disclosure of Significant Shareholdings 4 December 2008 PROPOSED PLACING OF £6.9 MILLION 10 November 2008 Clinical trials commence for extended warfarin sensitivity test 4 November 2008 CYP450 2C9 test launch. 31 October 2008 Warfarin Sensitivity study results. Update on proposed issue of American Depositary Shares. 25 September 2008 Osmetech plc (OMH.L), the international molecular diagnostics business, today announces interim results for the 6 months ended 30 June 2008 22 September 2008 Osmetech and QIAGEN sign development and supply agreement for QIAplex-based respiratory viral molecular test 12 September 2008 Osmetech plc Announces Initial Public Offering of American Depositary Shares 12 August 2008 Board Changes 30 July 2008 Osmetech announces first shipments of new eSensor® XT-8 platform and Warfarin Sensitivity Test 22 July 2008 Osmetech Says FDA Clearance of Its Warfarin Test Will Help Expand Menu, Installed Base 21 July 2008 FDA clears Osmetech's Warfarin Sensitivity Test and new eSensor® XT-8 platform 28 March 2008 Osmetech plc preliminary results for the 12 months ended 31 December 2007 12 March 2008 Osmetech licenses Roche polymerase technology 12 February 2008 Marshfield Clinic Discovers Gene Variant 7 January 2008 Warfarin test submitted for FDA approval All News March 24-28, 2010 American College of Medical Genetics Albuquerque, NM April 14-16, 2010 G2 Molecular Diagnostics 2010 Cambridge, MA April 25-28, 2010 Clinical Virology Symposium (CVS) Daytona Beach, FL July 25-29, 2010 AACC/Clinical Lab Expo Anaheim, CA November 2-6, 2010 American Society of Human Genetics Washington DC November 15-17, 2010 Association for Molecular Pathology San Jose, CA December 4-7, 2010 American Society of Hematology Orlando, FL All Exhibitions & Conferences

About Us | Products | Applications | Resources | Investor Info. | News | Join Mailing List | Site Index | Legal

 

© Copyright 2008, Osmetech, all rights reserved